About 1 in 26 people will develop epilepsy at some point in their lifetime, making it one of the most common neurological conditions worldwide. Roughly 50 million people are living with it globally, and each year approximately 68 new cases are diagnosed per 100,000 people. It is far more prevalent than most people realize.
Epilepsy in the United States
CDC data from the 2021–2023 National Health Interview Survey counted over 3.1 million U.S. adults with active epilepsy. The largest share, nearly 1.4 million, falls in the 18 to 44 age group. Another 1.1 million are between 45 and 64, and roughly 600,000 are 65 or older. When you add children, the total is significantly higher, though pediatric estimates are tracked separately and vary by survey year.
These numbers make epilepsy roughly as common in the U.S. as rheumatoid arthritis and considerably more common than conditions like multiple sclerosis or Parkinson’s disease.
Who Gets Epilepsy and When
Epilepsy follows a distinctive pattern across the lifespan: diagnoses peak in two age groups, the very young and the elderly. Infants and young children are vulnerable because of genetic factors, birth-related injuries, and developmental brain differences. Rates then dip through early and middle adulthood before climbing again after age 60, when strokes, brain tumors, and neurodegenerative conditions become more common triggers.
Overall prevalence tends to increase with age, meaning the oldest segments of the population carry the highest burden. Men face a slightly higher lifetime risk than women. Roughly 1 in 21 males will develop epilepsy over a lifetime, compared to about 1 in 28 females. By age 50, cumulative risk sits around 1.6%. By age 80 it doubles to 3%.
Rates Vary Widely by Country
Where you live has a major impact on your likelihood of being diagnosed. In high-income countries, about 49 people per 100,000 receive a new epilepsy diagnosis each year. In low- and middle-income countries, that figure can reach 139 per 100,000, nearly three times higher. The gap is driven by factors like limited prenatal care, higher rates of infectious diseases that affect the brain (such as malaria and neurocysticercosis), more frequent traumatic injuries, and fewer preventive health resources.
A large meta-analysis published in Neurology calculated a pooled global incidence of about 61 new cases per 100,000 person-years, confirming that epilepsy is not rare in any part of the world but hits harder in regions with fewer resources.
What Causes It
In about 40% of cases worldwide, no identifiable cause is found. These were historically called “idiopathic” epilepsies and are now generally understood to have a genetic basis, even when no single gene can be pinpointed. The remaining 60% fall into categories where a structural or metabolic cause can be identified: stroke, traumatic brain injury, brain infections, tumors, or developmental abnormalities present from birth.
The balance between known and unknown causes shifts depending on age. In children, genetic and developmental factors dominate. In older adults, stroke is the leading identifiable trigger. This is part of why epilepsy rates spike at both ends of the age spectrum.
How Treatable Is It
The majority of people with epilepsy can achieve seizure freedom with medication. When the first drug prescribed works, the path is straightforward. When it doesn’t, the odds are still favorable. A study tracking patients whose first medication failed found that 63.6% of them eventually became seizure-free after trying one or more additional drugs, going through an average of about two medications before finding the right fit.
That said, roughly a third of people with epilepsy continue to have seizures despite trying multiple treatments. This group, often described as having drug-resistant epilepsy, may be candidates for surgery, nerve stimulation devices, or specialized diets. The distinction matters because uncontrolled seizures carry real risks, both in daily life and in terms of long-term health.
The Global Treatment Gap
One of the starkest realities about epilepsy worldwide is how many people go entirely untreated. Across developing countries, an estimated 56% of people with active epilepsy are either receiving no medication at all or are on inadequate treatment. In rural areas that figure climbs to roughly 73%, compared to about 47% in urban settings.
This gap exists not because effective medications are complicated or expensive (basic seizure drugs are among the cheapest medications in existence) but because of limited access to trained health workers, stigma that discourages people from seeking care, unreliable drug supply chains, and diagnostic barriers. The result is tens of millions of people experiencing preventable seizures.
Mental Health and Related Conditions
Epilepsy rarely exists in isolation. Depression affects anywhere from 4% to 43% of people with the condition, depending on the population studied and how depression is measured. Anxiety is similarly common, reported in 8% to 50% of people with epilepsy. These aren’t just reactions to living with a chronic condition. The same brain changes that cause seizures can independently disrupt mood regulation and emotional processing.
Psychosis occurs in about 7% of people with epilepsy, and clinically significant cognitive decline or dementia is reported in 8% to 17.5%. Children with epilepsy face particularly high rates of learning challenges: roughly a quarter experience cognitive difficulties, about 26% have writing-related learning disabilities, and between 23% and 70% need some form of educational support, depending on their seizure type and frequency.
Mortality Risk
People with epilepsy do face a higher overall risk of premature death compared to the general population. The most concerning, though relatively rare, outcome is sudden unexpected death in epilepsy, or SUDEP. For the average person with epilepsy, the annual risk of SUDEP is about 1 in 1,000. But that risk is not evenly distributed. People who experience frequent generalized tonic-clonic seizures (the type involving full-body convulsions and loss of consciousness) face a dramatically elevated risk, as high as 10 to 15 times greater when more than three of these seizures occur in a year.
The mechanism behind SUDEP is not fully understood, but it typically occurs during or shortly after a seizure and is thought to involve disruptions in breathing or heart rhythm. The single most effective way to reduce the risk is achieving better seizure control, which circles back to the importance of access to proper treatment.